JP3471780B2 - 新規ペプチド - Google Patents

新規ペプチド

Info

Publication number
JP3471780B2
JP3471780B2 JP2001512558A JP2001512558A JP3471780B2 JP 3471780 B2 JP3471780 B2 JP 3471780B2 JP 2001512558 A JP2001512558 A JP 2001512558A JP 2001512558 A JP2001512558 A JP 2001512558A JP 3471780 B2 JP3471780 B2 JP 3471780B2
Authority
JP
Japan
Prior art keywords
amino acid
peptide
group
lys
ghrelin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2001512558A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2001007475A1 (ja
Inventor
賢治 寒川
将康 児島
洋司 細田
壽之 松尾
義春 南竹
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JPWO2001007475A1 publication Critical patent/JPWO2001007475A1/ja
Application granted granted Critical
Publication of JP3471780B2 publication Critical patent/JP3471780B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/06Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/461Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from fish
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/463Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from amphibians
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/465Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from birds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702Regulators; Modulating activity
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00Genetically modified animals
    • A01K2217/05Animals comprising random inserted nucleic acids (transgenic)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2001512558A 1999-07-23 2000-07-24 新規ペプチド Expired - Lifetime JP3471780B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
JP11-210002 1999-07-23
JP21000299 1999-07-23
JP11-338841 1999-11-29
JP33884199 1999-11-29
JP2000-126623 2000-04-26
JP2000126623 2000-04-26
PCT/JP2000/004907 WO2001007475A1 (en) 1999-07-23 2000-07-24 Novel peptides

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2003271241A Division JP4227857B2 (ja) 1999-07-23 2003-07-07 新規ペプチド

Publications (2)

Publication Number Publication Date
JPWO2001007475A1 JPWO2001007475A1 (ja) 2003-02-18
JP3471780B2 true JP3471780B2 (ja) 2003-12-02

Family

ID=27329078

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2001512558A Expired - Lifetime JP3471780B2 (ja) 1999-07-23 2000-07-24 新規ペプチド
JP2003271241A Expired - Lifetime JP4227857B2 (ja) 1999-07-23 2003-07-07 新規ペプチド

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2003271241A Expired - Lifetime JP4227857B2 (ja) 1999-07-23 2003-07-07 新規ペプチド

Country Status (16)

Country Link
US (5) US7385026B1 (enExample)
EP (3) EP1197496B8 (enExample)
JP (2) JP3471780B2 (enExample)
KR (1) KR100827973B1 (enExample)
CN (2) CN100506844C (enExample)
AT (2) ATE366813T1 (enExample)
AU (2) AU784035B2 (enExample)
BR (2) BRPI0012688B8 (enExample)
CA (2) CA2380058C (enExample)
CY (2) CY1107724T1 (enExample)
DE (2) DE60043361D1 (enExample)
DK (2) DK1795598T3 (enExample)
ES (3) ES2288151T3 (enExample)
IL (2) IL147652A0 (enExample)
PT (2) PT1197496E (enExample)
WO (1) WO2001007475A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005120484A1 (ja) * 2004-06-09 2005-12-22 Kurume University グレリンの生理学的機能のレギュレーター

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7385026B1 (en) 1999-07-23 2008-06-10 Kenji Kangawa Modified ghrelin polypeptides
CA2392019A1 (en) * 1999-11-22 2001-05-31 Zymogenetics, Inc. Method of forming a peptide-receptor complex with zsig33
US6897286B2 (en) 2000-05-11 2005-05-24 Zymogenetics, Inc. Zsig33-like peptides
US7141646B2 (en) 2000-05-12 2006-11-28 Kaneka Corporation Method of purifying vinyl polymer
JP2004514651A (ja) 2000-05-30 2004-05-20 メルク エンド カムパニー インコーポレーテッド グレリン類似体
US20020187938A1 (en) * 2000-07-24 2002-12-12 Romano Deghenghi Ghrelin antagonists
EP1493747B1 (en) * 2002-04-11 2012-12-19 Daiichi Sankyo Company, Limited Process for producing modified peptide
CA2471879C (en) * 2002-05-21 2014-02-25 Daiichi Suntory Pharma Co., Ltd. Pharmaceutical composition containing ghrelin
US20040076645A1 (en) * 2002-07-19 2004-04-22 Bachmann Martin F. Ghrelin-carrier conjugates
AU2003254119B2 (en) 2002-07-23 2007-11-29 Ipsen Pharma S.A.S. Ghrelin analogs
TWI331922B (en) 2002-08-09 2010-10-21 Ipsen Pharma Sas Growth hormone releasing peptides
MXPA05002991A (es) * 2002-09-18 2005-10-05 Univ Montreal Ct Hospitalier Chum Analogos de ghrh.
EP1407779A1 (en) 2002-10-10 2004-04-14 Gastrotech A/S Use of ghrelin for treating low body weight and body fat in gastrectomized individuals
JP4467518B2 (ja) * 2003-04-30 2010-05-26 賢治 寒川 肝障害予防治療剤
EP1633397A2 (en) * 2003-06-04 2006-03-15 Eli Lilly And Company Anti-ghrelin fab antibodies
US20060233788A1 (en) * 2003-09-05 2006-10-19 Heiman Mark L Anti-ghrelin antibodies
CN1321131C (zh) * 2003-12-26 2007-06-13 李宁 猪Ghrelin衍生物及其编码基因与应用
CA2553594A1 (en) * 2004-01-20 2005-07-28 Cytos Biotechnology Ag Particle-induced ghrelin immune response
US7026175B2 (en) 2004-03-29 2006-04-11 Applied Materials, Inc. High throughput measurement of via defects in interconnects
WO2005097831A2 (en) * 2004-04-07 2005-10-20 Gastrotech Pharma A/S Uses of isolated binding members capable of binding specifically to secretagogues
US20080171700A1 (en) * 2004-04-07 2008-07-17 Gastrotech Pharma A/S Use Of Secretagogue For The Teatment Of Ghrelin Deficiency
WO2005097830A2 (en) * 2004-04-07 2005-10-20 Aditech Pharma Ab Uses of isolated binding members capable of reducing the biological activity of secretagogue compounds
CA2566703A1 (en) * 2004-05-11 2005-11-24 Vishwa Deep Dixit Methods of inhibiting proinflammatory cytokine expression using ghrelin
CA2569235A1 (en) * 2004-07-14 2006-02-23 Eli Lilly And Company Anti-ghrelin antibodies
EP1812044A2 (en) * 2004-10-27 2007-08-01 Gastrotech Pharma A/S Uses of growth hormone secretagogues in the treatment of individuals suffering from renal and/or liver failure
WO2006045313A2 (en) * 2004-10-27 2006-05-04 Gastrotech Pharma A/S Uses of secretagogues for treatment of organ transplant patients
US20080300180A1 (en) * 2004-11-30 2008-12-04 Gastrotech Pharma A/S Growth Hormone Secretagogue Receptor 1A Ligands
JP4843827B2 (ja) * 2005-02-23 2011-12-21 国立大学法人京都大学 膵臓β細胞の再生促進剤及び膵臓β細胞におけるインスリン産生促進剤
EP1856154A1 (en) * 2005-02-23 2007-11-21 Eli Lilly And Company Humanized anti-ghrelin antibodies
RU2427587C2 (ru) * 2005-09-28 2011-08-27 Ипсен Фарма С.А.С. Аналоги грелина
ES2740108T3 (es) 2005-09-29 2020-02-05 Ipsen Pharma Composición para uso en el tratamiento de dismotilidad gastrointestinal
US20090305969A1 (en) * 2005-11-21 2009-12-10 Noboru Murakami Skin Repair Accelerating Therapeutic Agent Containing Desacyl Ghrelin and Derivatives Thereof as Active Ingredient
US20090181888A1 (en) * 2005-11-21 2009-07-16 Noboru Murakami Skin Repair Accelerating Therapeutic Agent Containing Ghrelin and Derivatives Thereof or Substance Acting On GHS-R1a as Active Ingredient
WO2007106385A2 (en) 2006-03-10 2007-09-20 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Use of a ghrelin agonist to improve the catabolic effects of glucocorticoid treatment
CN101443358B (zh) 2006-03-13 2016-05-11 利亚特·明茨 生长素释放肽剪接变体在治疗恶病质和/或压食和/或厌食-恶病质和/或营养不良和/或脂肪营养障碍和/或肌肉消耗和/或刺激食欲中的用途
CN101500602A (zh) * 2006-08-01 2009-08-05 斯克里普斯研究院 控制肥胖症的疫苗及方法
JPWO2008018600A1 (ja) 2006-08-11 2010-01-07 国立大学法人 宮崎大学 グレリン及びその誘導体又はGHS−R1aに作用する物質を有効成分とする脊髄神経修復促進治療剤
WO2008018597A1 (fr) * 2006-08-11 2008-02-14 University Of Miyazaki Agent thérapeutique permettant d'accélérer la réparation des nerfs rachidiens comprenant en tant que matière active de la désacyl ghréline ou un dérivé de celle-ci
MX2009003246A (es) 2006-09-27 2009-07-29 Ipsen Pharma Sas Análogos de ghrelina sustituidos en el terminal n.
HRP20160303T1 (hr) 2008-05-23 2016-04-22 Daiichi Sankyo Company, Limited Peptid koji je sposoban produljiti vrijeme polu-života pogodnih peptida u plazmi
NZ606427A (en) 2009-02-03 2014-10-31 Amunix Operating Inc Extended recombinant polypeptides and compositions comprising same
WO2010132580A2 (en) * 2009-05-12 2010-11-18 The Administrators Of The Tulane Educational Fund Methods of inhibiting the ghrelin/growth hormone secretatogue receptor pathway and uses thereof
US9724381B2 (en) 2009-05-12 2017-08-08 The Administrators Of The Tulane Educational Fund Methods of inhibiting the ghrelin/growth hormone secretatogue receptor pathway and uses thereof
US9078868B2 (en) 2010-01-15 2015-07-14 University Of Miyazaki Therapeutic agent for accelerating recovery of animal under medical treatment
CA2805406A1 (en) 2010-06-16 2011-12-22 Mcgill University Growth hormone secretatogue receptor antagonists and uses thereof
WO2012117592A1 (ja) 2011-03-03 2012-09-07 国立大学法人宮崎大学 高体温治療剤
JP5560248B2 (ja) * 2011-09-07 2014-07-23 花王株式会社 ジペプチド誘導体及びその製造方法
EP2819788B1 (en) 2012-02-27 2018-08-22 Amunix Operating Inc. Xten conjugate compositions and methods of making same
MX349035B (es) 2012-05-17 2017-07-07 Extend Biosciences Inc Portadores para el suministro mejorado de farmaco.
US9486503B2 (en) 2012-10-04 2016-11-08 Shionogi & Co., Ltd. Medicinal agent for suppressing malignant tumor metastasis
AU2013335678B9 (en) * 2012-10-24 2024-12-12 Daiichi Sankyo Company,Limited Therapeutic agent for amyotrophic lateral sclerosis
JP6143270B2 (ja) * 2013-01-31 2017-06-07 学校法人東京薬科大学 マイオスタチン阻害ペプチド
EP2979702A4 (en) * 2013-03-25 2016-11-16 Zeria Pharm Co Ltd GASTROKINETIC POSTPRANDIAL MEDIUM
US9616109B2 (en) 2014-10-22 2017-04-11 Extend Biosciences, Inc. Insulin vitamin D conjugates
US9789197B2 (en) 2014-10-22 2017-10-17 Extend Biosciences, Inc. RNAi vitamin D conjugates
CA2964463C (en) 2014-10-22 2024-02-13 Extend Biosciences, Inc. Therapeutic vitamin d conjugates
CN109879935B (zh) * 2019-03-04 2020-11-20 南京工业大学 一种多肽的液相合成方法
BR112022009217A2 (pt) 2019-11-13 2022-08-02 Amunix Pharmaceuticals Inc Polipeptídeos xten com código de barras e composições destes, e métodos para produzir e usar os mesmos
KR20250075704A (ko) 2022-09-30 2025-05-28 익스텐드 바이오사이언시즈, 인크. 장기-지속형 부갑상선 호르몬
CN120818010B (zh) * 2025-09-18 2025-12-05 天津科技大学 一种来自植物乳杆菌属细胞外囊泡的短肽及其应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5194596A (en) * 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
IL98910A0 (en) * 1990-07-24 1992-07-15 Polygen Holding Corp Polypeptide compounds having growth hormone releasing activity and pharmaceutical compositions containing them
US5663146A (en) * 1991-08-22 1997-09-02 Administrators Of The Tulane Educational Fund Polypeptide analogues having growth hormone releasing activity
DE69332471T2 (de) * 1992-04-07 2003-08-28 The Scripps Research Institute, La Jolla Verfahren zur herstellung modifizierten proteine
CA2216755A1 (en) * 1995-03-31 1996-10-03 Brian Lee Buckwalter Peptides with growth promotion properties
IL118473A0 (en) 1995-06-02 1996-09-12 Suntory Ltd Staphylococcus aureus V8 protease genes coding therefor and a method for the production thereof
JP3982866B2 (ja) 1996-03-04 2007-09-26 アスビオファーマ株式会社 分泌型Kex2誘導体の製造方法
CA2198966C (en) 1996-03-04 2011-06-21 Yuji Suzuki Method for cleaving chimeric protein using processing enzyme
JP4335318B2 (ja) 1997-03-24 2009-09-30 ザイモジェネティクス,インコーポレイティド モチリン相同体
IL139686A0 (en) * 1998-06-02 2002-02-10 Genentech Inc Secreted and transmembrane polypeptides and nucleic acids encoding the same
CN1120846C (zh) * 1999-02-13 2003-09-10 中国人民解放军军事医学科学院基础医学研究所 生长激素释放肽及其应用
US6420521B1 (en) * 1999-06-30 2002-07-16 Zymogenetics, Inc. Short gastrointestinal peptides
US7385026B1 (en) * 1999-07-23 2008-06-10 Kenji Kangawa Modified ghrelin polypeptides

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Cellular and Molecular Neurobiology,1998年,Vol.18,No.1,p.101−123
Nature,1999年,Vol.402,p.656−660

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005120484A1 (ja) * 2004-06-09 2005-12-22 Kurume University グレリンの生理学的機能のレギュレーター

Also Published As

Publication number Publication date
US8524871B2 (en) 2013-09-03
JP4227857B2 (ja) 2009-02-18
EP1197496B8 (en) 2007-10-03
CN1362968A (zh) 2002-08-07
ATE366813T1 (de) 2007-08-15
DK1795598T3 (da) 2010-02-01
CA2380058A1 (en) 2001-02-01
ES2288151T3 (es) 2008-01-01
EP1795598A1 (en) 2007-06-13
AU6023100A (en) 2001-02-13
CY1107724T1 (el) 2013-04-18
CN101693736A (zh) 2010-04-14
KR20020026543A (ko) 2002-04-10
EP1197496A4 (en) 2002-11-20
ES2335235T3 (es) 2010-03-23
DE60043361D1 (de) 2009-12-31
US9573986B2 (en) 2017-02-21
JP2004000251A (ja) 2004-01-08
ES2401939T3 (es) 2013-04-25
CA2696819C (en) 2015-07-07
EP1795598B1 (en) 2009-11-18
AU2006201580B2 (en) 2009-01-08
US20110184153A1 (en) 2011-07-28
CY1109714T1 (el) 2014-08-13
IL147652A0 (en) 2002-08-14
PT1197496E (pt) 2007-08-29
DE60035502T2 (de) 2008-03-20
CN100506844C (zh) 2009-07-01
EP1197496A1 (en) 2002-04-17
US20090170763A1 (en) 2009-07-02
WO2001007475A1 (en) 2001-02-01
US8227570B2 (en) 2012-07-24
US20100240866A1 (en) 2010-09-23
US7385026B1 (en) 2008-06-10
AU2006201580A1 (en) 2006-05-18
KR100827973B1 (ko) 2008-05-21
AU784035B2 (en) 2006-01-19
CA2380058C (en) 2011-08-09
PT1795598E (pt) 2010-01-05
IL147652A (en) 2010-04-29
ATE449174T1 (de) 2009-12-15
EP1197496B1 (en) 2007-07-11
EP2119785A1 (en) 2009-11-18
CA2696819A1 (en) 2001-02-01
US9938332B2 (en) 2018-04-10
US20130172251A1 (en) 2013-07-04
BRPI0012688B8 (pt) 2021-05-25
BRPI0012688B1 (pt) 2018-06-05
DE60035502D1 (de) 2007-08-23
BR0012688A (pt) 2002-04-16
CN101693736B (zh) 2020-09-11
DK1197496T3 (da) 2007-10-22
EP2119785B1 (en) 2013-03-13

Similar Documents

Publication Publication Date Title
JP3471780B2 (ja) 新規ペプチド
JPWO2001007475A1 (ja) 新規ペプチド
CA2491946C (en) Ghrelin analogs
TW200408402A (en) Growth hormone releasing peptides
US11572399B2 (en) Long-acting GIP peptide analogues
JP2007526900A (ja) Gh−rhのアンタゴニスト誘導体(2003)
JP2002530432A (ja) Gh−rh阻害igf−iおよびiiの拮抗類似体
CN113072617B (zh) 一种多肽化合物及其应用
KR101202242B1 (ko) 그렐린 유사체

Legal Events

Date Code Title Description
TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20030806

R150 Certificate of patent or registration of utility model

Ref document number: 3471780

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20080912

Year of fee payment: 5

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20090912

Year of fee payment: 6

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20100912

Year of fee payment: 7

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110912

Year of fee payment: 8

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120912

Year of fee payment: 9

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130912

Year of fee payment: 10

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130912

Year of fee payment: 10

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140912

Year of fee payment: 11

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term